Evidence map›Paper›PMID 41130981›Full record

ArticleNature communications2025

FAP

Jiacheng Ma, Yan Huang, Jie Chen, Yang Li, Rongyan Yao, Xiubin Li, Qiyang Liang, Xinran Chen, Cheng Peng, Kan Liu and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. FAPNature communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jiacheng Ma *Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Yan Huang *Senior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Jie Chen *State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China.
Yang Li *State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China.ORCID http://orcid.org/0000-0002-2009-7079
Rongyan YaoState Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China.
Xiubin LiSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-6835-6340
Qiyang LiangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Xinran ChenSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Cheng PengSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Kan LiuSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Yuanjun ZhaiState Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China.
Xu ZhangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-6908-6768
Xin MaSenior Department of Urology, Chinese PLA General Hospital, Beijing, China. mxin301@126.com.ORCID http://orcid.org/0000-0001-8257-4670
Xiaowen WangState Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China. wangxiaowen@ncpsb.org.cn.
Qingbo HuangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China. gdhuangqingbo@163.com.ORCID http://orcid.org/0000-0003-2894-0187
Fuchu HeState Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China. hefc@bmi.ac.cn.ORCID http://orcid.org/0000-0002-1094-4019

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81988101National Natural Science Foundation of China (National Science Foundation of China) 82273412
6 · The paper itself

Abstract

Tumor thrombus (TT) worsens prognosis and complicates surgery in renal cell carcinoma (RCC), yet its formation mechanisms remain unclear. Here, we perform integrative single-cell and spatial transcriptomic analyses on 71 tissues and 48 sections from RCC patients with or without TT. The cellular and spatial atlas reveals distinct TT-associated tumor microenvironment remodeling characterized by the enrichment of FAP

Indexed as

Carcinoma, Renal CellFibroblastsGelatinasesKidney NeoplasmsSerine EndopeptidasesThrombosisTumor MicroenvironmentCancer-Associated FibroblastsCell Line, TumorEndopeptidasesFemaleFibroblast Activation Protein AlphaGene Expression Regulation, NeoplasticHumansKiller Cells, NaturalMaleEndopeptidasesFibroblast Activation Protein AlphaGelatinasesMembrane ProteinsSerine Endopeptidases

Identifiers

PMID41130981
PMCPMC12549817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.